Podcasts about amarin

My co-host Ken Suzan and I are welcoming you to episode 171 of our podcast IP Fridays! Today's interview guest is the president of the German Patent and Trademark Office Eva Schewior! But before we jump into this very interesting interview, I have news for you: The US Supreme Court has taken up an important patent law case concerning so-called “skinny labels” for generic drugs. Specifically, the highest US court is reviewing a case in which Amarin accuses generic drug manufacturer Hikma of inciting doctors to use the cholesterol drug Vascepa in violation of patents by providing a limited package insert. In two landmark decisions, the UPC Court of Appeal clarified the criteria for inventive step and essentially confirmed the EPO’s typical “problem-solution” approach (Amgen v Sanofi and Meril v Edwards). However, experts are not entirely sure whether the Court of Appeal’s decisions, particularly those relating to the determination of the closest prior art, deviate from EPO practice. As a result of Brexit, mutual recognition of trademark use between the EU and the UK will cease to apply from January 1, 2026. Use of a trademark only in the UK will then no longer count as use of an EU trademark for the purpose of maintaining rights – and conversely, EU use will no longer count for British trademarks. Bayer is attacking several mRNA vaccine manufacturers in the US (Pfizer, BioNTech, Moderna, and J&J separately). The core allegation: patent infringements relating to old (Monsanto) patents on mRNA stabilization; Bayer is seeking damages, not sales bans. DISCO Pharmaceuticals from Cologne signs an exclusive license agreement with Amgen (potentially up to USD 618 million plus royalties) for novel cancer therapies targeting surface structures. Relevant from an IP perspective: license scope, milestones, data/know-how allocation. And now let's jump into the interview with Eva Schewior! The German IP System in Transition: Key Insights from DPMA President Eva Schewior In an in-depth conversation on the IP Fridays podcast, Eva Schewior, President of the German Patent and Trademark Office (DPMA), outlined how Germany's IP system is responding to rising demand, technological change, and a fundamentally altered European patent landscape. The interview offers valuable insights for innovators, companies, and IP professionals navigating patent, trademark, and design protection in Europe. Sustained Demand and Procedural Efficiency Despite the introduction of the Unitary Patent system, national German IP rights continue to see strong and growing demand. According to Schewior, application numbers at the DPMA have been increasing for years, which she views as a strong vote of confidence in the quality and reliability of German IP rights. At the same time, this success creates pressure on examination capacity. The average duration of patent proceedings at the DPMA is currently around three years and two months from filing to grant, provided applicants request examination early and avoid extensions. Internationally, this timeframe remains competitive. Nevertheless, shortening procedures remains a strategic priority. Search requests alone have risen by almost 50% over the past decade, yet the DPMA still delivers search reports on time in around 90% of cases. To better reflect applicant needs, the DPMA distinguishes between two main user groups: applicants seeking a rapid grant, often as a basis for international filings, and applicants primarily interested in a fast, high-quality initial assessment through search or first examination. Future procedural adjustments are being considered to better serve both groups. The Role of Artificial Intelligence Artificial intelligence already plays a practical role at the DPMA, particularly in patent search, classification, and the translation of Asian patent literature. Schewior emphasized that the office is closely monitoring rapid developments in AI to assess where these tools can further improve efficiency. However, she made clear that AI will remain a supporting technology. In public administration, and especially in IP examination, final decisions must always be taken and reviewed by humans. AI is seen as a way to relieve examiners of routine tasks so they can focus on substantive examination and quality. Maintaining and Monitoring Examination Quality Quality assurance is a central pillar of the DPMA's work. Schewior reported consistently positive feedback from users, but stressed that maintaining quality is a continuous task. The office applies systematic double checks for grants and refusals and uses internal quality management tools to randomly review searches and first office actions during ongoing proceedings. External feedback is equally important. The DPMA's User Advisory Board, which includes patent attorneys, startups, and patent information centers, plays a key role in identifying issues and suggesting improvements. Several of its recommendations have already been implemented. Trademark Filings and Bad-Faith Applications The trademark side of the DPMA has experienced particularly strong growth. In 2025, the office received around 95,000 trademark applications, an increase of approximately 18% compared to the previous year. Much of this growth came from abroad, especially from China. While new trademark types such as sound marks, multimedia marks, and holograms have so far seen only moderate uptake, word marks and figurative marks remain dominant. A growing challenge, however, is the rise in bad-faith trademark filings. The DPMA has responded by intensively training examiners to identify and handle such cases. Procedural reforms following EU trademark law modernization have also shifted competencies. Applicants can now choose whether to bring revocation and invalidity actions before the courts or directly before the DPMA. While courts may act faster, proceedings before the DPMA involve significantly lower financial risk, as each party generally bears its own costs. Accelerated Examination as a Practical Tool Despite rising filing numbers, the DPMA aims to avoid significant delays in trademark proceedings. Organizational restructuring within the trademark department is intended to balance workloads across teams. Schewior highlighted the option of accelerated trademark examination, available for a relatively modest additional fee. In practice, this can lead to registration within a matter of weeks, without affecting priority, since the filing date remains decisive. New Protection for Geographical Indications A major recent development is the extension of EU-wide protection for geographical indications to craft and industrial products. Since late 2025, the DPMA acts as the national authority for German applications in this area. The first application has already been filed, notably for a traditional German product. Under the new system, applications undergo a national examination phase at the DPMA before being forwarded to the EUIPO for final decision. Products eligible for protection must originate from a specific region and derive their quality or reputation from that origin, with at least one production step taking place there. The EU estimates that around 40 German products may qualify. Outreach, SMEs, and Education Schewior underlined the DPMA's statutory duty to inform the public about IP rights, with a particular focus on small and medium-sized enterprises. The office has significantly expanded its presence on platforms such as LinkedIn and YouTube, offering accessible and practical IP content. Studies show that fewer than 10% of European SMEs use IP rights, despite evidence that IP-owning companies generate higher revenues. To address this gap, the DPMA is expanding outreach formats, strengthening cooperation with educational institutions, and publishing new empirical studies, including a forthcoming analysis of patenting behavior among innovative German startups conducted with WIPO. Strategic Challenges Ahead Looking forward, Schewior identified several key challenges: insufficient awareness of IP protection among SMEs and startups, a tendency in some sectors to rely solely on trade secrets, and the growing problem of product and trademark piracy linked to organized crime. From an institutional perspective, the DPMA must remain attractive and competitive in a European system offering multiple routes to protection. This requires legally robust decisions, efficient procedures, qualified staff, and continuous investment in IT and training. Careers at the DPMA Finally, Schewior highlighted recruitment as a strategic priority. The DPMA recently hired around 50 new patent examiners and continues to seek experts in fields such as electrical engineering, e-mobility, IT, and aerospace, as well as IT specialists, lawyers, and staff in many other functions. She emphasized the DPMA's role as Europe's largest national patent office and a globally significant, stable, and family-friendly employer at the forefront of technological development. German and European Patents as Complementary Options In her closing remarks, Schewior addressed the post-UPC patent landscape. Rather than competing, German and European patent systems complement each other. For many SMEs, a German patent alone may be sufficient, particularly where Germany is the core market. At the same time, the possibility of holding both a European patent and a national German patent offers strategic resilience, as national protection can survive even if a European patent is revoked. Her key message was clear: the range of options has never been broader, but making informed strategic choices is more important than ever. If you would like, I can also adapt this article for a specialist legal audience, condense it for a magazine format, or rework it as a thought-leadership piece for LinkedIn or your website. Rolf Claessen: Today's interview guest is Eva Schewior. If you don't know her yet, she is the President of the German Patent and Trademark Office. Thank you very much for being here. Eva Schewior: I'm very happy that you're having me today. Thank you, Mr. Claessen. Rolf Claessen: Shortening the length of procedures has been a stated goal since you took office. What is the current situation, and which measures are in place to achieve this goal? Eva Schewior: First of all, I'm very glad that German IP rights are in high demand. Even though applicants in Europe have multiple options today to obtain protection for their innovations, we have seen increasing application numbers for years at my office, even after the introduction of the Unitary Patent system. I see this as very positive feedback for our work. It is clear, however, that the high number of applications leads to a constantly increasing workload. At the same time, we want to remain attractive for our applicants. This means we must offer not only high-quality IP rights but also reasonable durations of proceedings. Ensuring this remains a central and permanent objective of our strategy. The average duration of proceedings from filing to grant is currently about three years and two months, provided that applicants file an examination request within the first four months after application and do not request extensions of time limits. In other cases, the average duration of proceedings is admittedly longer. With these three years and two months, we do not have to shy away from international comparison. Nonetheless, we strive to get better. In the last few years, we were able to improve the number of concluded proceedings or to keep them at a high level. In some areas, we were even able to shorten durations of proceedings a bit, though not yet to the extent that we would have wished for. Our efforts are often overtaken by the increasing demand for our services. Just to give you an example, in the last ten to fifteen years, search requests increased by nearly fifty percent. Despite this, we managed to deliver search reports in ninety percent of all cases in time, so that customers have enough time left to take a decision on a subsequent application. I have to admit that we are not equally successful with the first official communication containing the first results of our examination. Here, our applicants need a bit more patience due to longer durations of proceedings. But I think I do not have to explain to your expert audience that longer processing times depend on various reasons, which are in no way solely to be found on our side as an examination office. To further reduce the length of proceedings, we need targeted measures. To identify them, we have analyzed the needs of our applicants. It has been shown that there are two main interests in patent procedures. About three quarters of our applicants have a very strong interest in obtaining a patent. They mainly expect us to make fast decisions on their applications. Here we find applicants who want to have their invention protected within Germany but often also wish for subsequent protection outside Germany. The remaining quarter consists of applicants that are solely interested in a fast and high-quality first assessment of the application by means of a search or a first official examination. We observe that these applicants use our services before they subsequently apply outside Germany. This latter group has little interest in continuing the procedure before my office here in Germany. We are currently considering how we can act in the best interest of both groups. What I can certainly say is that we will continue to address this topic. And of course, in general, it can be said that if we want to shorten the duration of proceedings, we need motivated and highly skilled patent examiners. Therefore, we are currently recruiting many young colleagues for our offices in Munich and Jena, and we want to make our procedures more efficient by using new technical options, thus taking workload from patent examiners and enabling them to concentrate on their core tasks and on speedy examination. Rolf Claessen: Thank you very much. I also feel that the German Patent and Trademark Office has become quite popular, especially with the start of the UPC. Some applicants seem to find that it is a very clever option to also file national patents in Germany. Eva Schewior: I think you're perfectly right, and I think we will come to this point later. Rolf Claessen: In 2023, you mentioned artificial intelligence as an important tool for supporting patent examiners. What has happened regarding AI since then? Eva Schewior: Of course, we are already successfully using AI at our office. For instance, in the field of patent search, we use AI-based tools that make our examiners' work easier. We also use AI quite successfully for classification and for the translation of Asian patent literature into English. In the meantime, we have seen a rapid development of AI in the market. I think it is strategically imperative to get an overview and to make realistic assessments of what AI is capable of doing to make our procedures more efficient. Therefore, we are observing the market to find out where AI can perform tasks so that we enable examiners to concentrate on their core business. There are many ideas right now in our office where artificial intelligence can help us tackle challenges, for instance demographic change, which certainly also affects our office, and maintaining our quality standards. We will strategically promote new tools in this field to cope with these challenges. But this much is also clear: humans will always stay in our focus. Especially in public administration, I consider it a fundamental principle that in the end, decisions must be taken and reviewed by humans. AI may help us reach our goals in a more efficient way, but it can never replace patent or trademark examiners. Rolf Claessen: You have made quality improvements in patent examination a priority and have already implemented a number of measures. How would you describe the current situation? Eva Schewior: I often receive positive feedback from different sides that our users are very satisfied with the quality of our examination, and I'm very glad about that. But maintaining this quality standard is a permanent task, and we must not become careless here. For years, for instance, we have established double checks for all grants and rejections. In addition, we have introduced a quality management tool that enables us, even during the examination process, to randomly check the quality of first office communications and searches. This helps us detect critical trends and take appropriate countermeasures at a very early stage. What is also very important when it comes to patent quality is to actively ask our customers for their feedback. We do this in different ways. Just to give you an example, we have a User Advisory Board, which is a panel of external experts implemented a couple of years ago. Discussing questions of quality is regularly on the agenda of this board. We carefully listen to criticism, ideas, and suggestions, and we have already implemented some of them for the benefit of the office and our users. Rolf Claessen: The German Patent and Trademark Office, as the largest patent and trademark office in Europe, records very high numbers of trademark applications. What are you currently especially concerned with in the trademark area? Eva Schewior: In 2025, we saw around ninety-five thousand trademark applications. This is an increase of eighteen percent compared to the previous year, and I have to say that this took us by surprise. Especially applications from outside Germany, and above all from China, have risen significantly. It is of course challenging to cope with such a sudden increase on an organizational level. Another challenge is dealing with trademark applications filed in bad faith, which we are currently seeing more and more of. We have thoroughly trained our trademark examiners on how to identify and handle such applications. As regards the new types of trademarks, the rush has been moderate so far. Sound marks, multimedia marks, or holograms are apparently not yet common solutions for the majority of applicants. The key focus remains on word marks and combined word and figurative marks. Nevertheless, I believe that the new trademark types are a meaningful supplement and may play a greater role as digitization advances. The most significant changes, however, concern procedures. Applicants can now choose whether to file revocation or invalidity actions with the courts or with our office. While courts may proceed somewhat faster, the financial risk is higher. Before the DPMA, each party generally bears its own costs, apart from exceptional cases. Rolf Claessen: How does this dynamic filing development impact the duration of trademark proceedings? Eva Schewior: This is indeed a major organizational challenge. For a long time, our trademark department managed to keep durations of proceedings very short, especially with regard to registration. Despite the recent increases in applications, especially in 2025, we hope to avoid a significant extension of processing times. We have restructured the organization of the trademark department to distribute applications more equally among teams. Applicants should also be aware that it is possible to request accelerated examination for a relatively moderate fee of two hundred euros. This often leads to registration within a very short time. The filing date, of course, always determines priority. Rolf Claessen: Since December 2025, the EU grants protection not only for agricultural products but also for craft and industrial products through geographical indications. Has your office already received applications? Eva Schewior: Yes, we have received our first application, and interestingly it concerns garden gnomes. Protected geographical indications are an important topic because they help maintain traditional know-how in regions and secure local jobs. The DPMA is the competent authority for Germany. Applications go through a national examination phase at our office before being forwarded to the EUIPO, which takes the final decision on EU-wide registration. Eligible products must originate from a specific region and derive their quality, reputation, or characteristics from that origin, with at least one production step taking place there. Rolf Claessen: The DPMA has expanded its outreach activities, including social media. What else is planned? Eva Schewior: Raising awareness of IP rights, especially among small and medium-sized enterprises, is part of our statutory duty. We currently use LinkedIn and YouTube to communicate IP topics in an understandable and engaging way. We also plan dedicated LinkedIn channels, for example for SMEs. Studies show that fewer than ten percent of European SMEs use IP rights, even though those that do earn significantly more on average. In 2026, we will further expand outreach activities, cooperate more closely with universities and educational institutions, and publish new studies, including one on the patenting behavior of innovative German start-ups conducted together with WIPO. Rolf Claessen: Where do you see the biggest future challenges in IP? Eva Schewior: Germany depends on innovation, but awareness of IP protection is still insufficient, particularly among SMEs and start-ups. Some companies deliberately avoid IP rights and rely on trade secrets, which I consider risky. Another growing concern is the increase in product and trademark piracy, often linked to organized crime. For our office, remaining attractive and competitive is crucial. Applicants have many options in Europe, so we need fast procedures, legally robust decisions, qualified staff, and modern IT systems. Rolf Claessen: The DPMA is currently recruiting. Which areas are you focusing on? Eva Schewior: Our focus is on patent examination and IT. We recently hired fifty new patent examiners and are particularly looking for experts in fields such as electrical engineering, e-mobility, IT, and aerospace. We are Europe's largest national patent office and offer meaningful, secure jobs with fair compensation and strong development opportunities. Rolf Claessen: Is there a final message you would like to share with our listeners? Eva Schewior: The Unitary Patent system has created many new options. German and European patent systems do not compete; they complement each other. For many SMEs, a German patent may already be sufficient, especially where Germany is the core market. Holding both European and national patents can also be a strategic advantage. My key message is: be aware of the options, stay informed, and choose your IP strategy deliberately. Rolf Claessen: Thank you very much for being on IP Fridays. Eva Schewior: Thank you for having me. It was a pleasure.

This episode covers: Cardiology This Week: A concise summary of recent studies Visceral adiposity: paradigm shift in HFpEF management Artificial Intelligence in echocardiography Milestones: ISIS-2 Host: Susanna Price Guests: Carlos Aguiar, Milton Packer, Rudolf de Boer Want to watch the episode? Go to: https://esc365.escardio.org/event/2175 Want to watch the extended interview on AI in echocardiography? Go to: https://esc365.escardio.org/event/2175?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. The ESC is not liable for any translated content of this video. The English language always prevails. Declarations of interests: Stephan Achenbach, Yasmina Bououdina, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. John-Paul Carpenter has declared to have potential conflicts of interest to report: stockholder Mycardium AI. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Rudolf de Boer has declared to have potential conflicts of interest to report: the institution of Rudolf de Boer has received research grants and/or fees from Alnylam, AstraZeneca, Abbott, Bristol-Myers Squibb, NovoNordisk, and Roche; Rudolf de Boer has had speaker engagements with and/or received fees from and/or served on an advisory board for Abbott, AstraZeneca, Bristol Myers Squibb, NovoNordisk, Roche, and Zoll; Rudolf de Boer received travel support from Abbott and NovoNordisk. Konstantinos Koskinas has declared to have potential conflicts of interest to report: honoraria from MSD, Daiichi Sankyo, Sanofi. Milton Packer has declared to have potential conflicts of interest to report: 89bio, Abbvie, Actavis, Altimmune, Alnylam, Amarin, Amgen, Ardelyx, ARMGO, AstraZeneca, Attralus, Biopeutics, Boehringer Ingelheim, Caladrius, Casana, CSL Behring, Cytokinetics, Daiichi Sankyo, Imara, Lilly, Medtronic, Moderna, Novartis, NovoNordisk, Pharmacocosmos, Regeneron, Roche, Salamandra. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

durée : 00:02:50 - Près de chez vous en Alsace - Ce week-end, Saint-Amarin devient la scène d'un événement pas comme les autres : la 2ᵉ édition de sa grande fête des arts, du spectacle vivant et de l'artisanat local. Un rendez-vous festif et accessible à tous, qui transforme tout le village en terrain de découvertes. Vous aimez ce podcast ? Pour écouter tous les autres épisodes sans limite, rendez-vous sur Radio France.

Join us for a powerful conversation with Amarin Trichanh, U.S. Army combat veteran, author of I Am My Sister's Keeper, and unstoppable advocate for military justice. On this episode, we delve into her inspiring life story—from surviving three combat tours in Iraq and Afghanistan, to bravely exposing widespread military sexual assault and abuse within the armed forces!Here's a glimpse of what you'll hear:

In this special episode on Fish Oil -  Facts, Fiction, and EPA our host, Dr. Neil Skolnik, will discuss the evidence distinguishing fish oil from EPA (Icosapent ethyl).  This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health John Osborne MD, PhD - Preventive cardiologist and lipidologist, Chief medical officer of Clear Cardio, LLC Selected References: Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280 Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098 Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 ADA Standards of Care: Diabetes Care 2025;48(Supplement_1):S207–S238 https://doi.org/10.2337/dc25-S010 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168  

This episode covers:  Cardiology this Week: A concise summary of recent studies Coronary sinus reducer: promise in refractory angina Best strategies to reach LDL cholesterol goals in high-risk patients Snapshots Host: Susanna Price Guests: Carlos Aguiar, Rasha Al-Lamee, J. Wouter Jukema, Steffen Petersen Want to watch that episode? Go to: https://esc365.escardio.org/event/1807 Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Rasha Al-Lamee has declared to have potential conflicts of interest to report: speaker's fees for Menarini pharmaceuticals, Abbott, Philips, Medtronic, Servier, Shockwave, Elixir. Advisory board: Janssen Pharmaceuticals, Abbott, Philips, Shockwave, CathWorks, Elixir. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis, Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

Host: Susanna Price Guest: J. Wouter Jukema Want to watch that extended interview on LDL management? Go to: https://esc365.escardio.org/event/1807?resource=interview Want to watch the full episode? Go to: https://esc365.escardio.org/event/1807 Disclaimer ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsors. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. J. Wouter Jukema has declared to have potential conflicts of interest to report: J. Wouter Jukema/his department has received research grants from and/or was speaker (CME accredited) meetings sponsored/supported by Abbott, Amarin, Amgen, Athera, Biotronik, Boston Scientific, Dalcor, Daiichi Sankyo, Edwards Lifesciences, GE Healthcare Johnson and Johnson, Lilly, Medtronic, Merck-Schering-Plough, Novartis, Novo Nordisk, Pfizer, Roche, Sanofi Aventis,Shockwave Medical, the Netherlands Heart Foundation, CardioVascular Research the Netherlands (CVON), the Netherlands Heart Institute and the European Community Framework KP7 Programme. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

This episode covers: Cardiology This Week: A concise summary of recent studies Relevance and management of ventricular ectopic beats  Lp(a) in cardiovascular risk management Mythbusters: A vegetarian diet lowers cardiovascular risk Host: Susanna Price Guests: Carlos Aguiar, Thomas Deneke, Kausik Ray Want to watch that episode? Go to: https://esc365.escardio.org/event/1802 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb and Novartis. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Thomas Deneke, Nicolle Kraenkel and Susanna Price have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Novo Nordisk, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Bristol Myers Squibb, Daiichi Sankyo, Sanofi Aventis, Novo Nordisk, Terumo. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Kausik Ray declared to have potential conflicts of interest to report: research grants from Amarin, Amgen, Daiichi Sankyo, Merck Sharp & Dohme, Pfizer, Regeneron, and Sanofi, consultant for Abbott, Amarin, Amgen, AstraZeneca, Bayer, Biologix, Boehringer Ingelheim, Cargene Therapeutics, CRISPR, CSL Behring, Eli Lilly and Company, Esperion, Kowa Pharmaceuticals, NewAmsterdam Pharma, Novartis, Novo Nordisk, Pfizer, Regeneron, Resverlogix, Sanofi, Scribe Therapeutics, Silence Therapeutics, Vaxxinity, and Viatris, honoraria for lectures from Novartis, BI, AZ, Novo Nordisk, Viatris, Amarin, Biologix Pharma, Sanofi, Amgen, Esperion, Daiichi Sankyo, Macleod and stock options New Amsterdam Pharma, Pemi 31, SCRIBE Therapeutics. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

ROMA (ITALPRESS) - Le malattie cardiovascolari sono la principale causa di morte in Italia con oltre 217mila decessi l'anno. Secondo le ultime stime del Global Burden of Disease, in Italia circa 9,6 milioni di individui sono affetti da malattie cardiovascolari, con 800 mila nuove diagnosi annuali e oltre 670 mila ricoveri ospedalieri imputabili a queste patologie. Nonostante l'efficacia delle terapie ipolipemizzanti, antidiabetiche e antipertensive, esiste un gruppo di pazienti che può rimanere esposto a rischio cardiovascolare residuo, ovvero la probabilità che ha una persona con malattia cardiovascolare di sviluppare nuovi eventi, spesso fatali, anche laddove trattata seguendo gli standard di cura. Al Rischio cardiovascolare residuo è dedicato un Manifesto promosso dalle società scientifiche, realizzato con il patrocinio di SID e SALUTEQUITA' e col contributo non condizionante di Amarin. Lo presenta Francesco Dentali, Presidente della Federazione delle Associazioni dei Dirigenti Ospedalieri Internisti.sat/mrv

Host: Emer Joyce Guest: Harald Jorstad Want to watch that extended interview? Go to: https://esc365.escardio.org/event/1795?resource=interview Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Harald Jorstad has declared to have potential conflicts of interest to report: unrestricted research grants to institution: Dutch Olympic Committee, Dutch Heart Foundation, Zon-Mw, Heart to Handle. Unrestricted, unrelated research grants to institution: Novartis, Amarin, Novo Nordisk, Sanofi. Unrelated advisory fees to institution: Amarin, Amgen. Emer Joyce has declared to have no potential conflicts of interest to report.

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly.  This episode covers: Cardiology This Week: A concise summary of recent studies Aortic aneurysms Return to elite sports after a severe cardiac event Milestones: CAST Host: Emer Joyce Guests: Carlos Aguiar, Jose Rodriguez Palomares, Harald Jorstad Want to watch that episode? Go to: https://esc365.escardio.org/event/1795 Disclaimer: ESC TV Today is supported by Bristol Myers Squibb. This scientific content and opinions expressed in the programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests: Stephan Achenbach, Emer Joyce, Nicolle Kraenkel and Jose Rodriguez Palomares have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, BiAL, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, GSK, Lilly, Novartis, Pfizer, Sanofi, Servier, Takeda, Tecnimede. Davide Capodanno has declared to have potential conflicts of interest to report: Sanofi Aventis, Novo Nordisk, Terumo. Harald Jorstad has declared to have potential conflicts of interest to report: unrestricted research grants to institution: Dutch Olympic Committee, Dutch Heart Foundation, Zon-Mw, Heart to Handle. Unrestricted, unrelated research grants to institution: Novartis, Amarin, Novo Nordisk, Sanofi. Unrelated advisory fees to institution: Amarin, Amgen. Steffen Petersen has declared to have potential conflicts of interest to report: consultancy for Circle Cardiovascular Imaging Inc. Calgary, Alberta, Canada. Emma Svennberg has declared to have potential conflicts of interest to report: Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Johnson & Johnson.

In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Residual Risk, Triglycerides and how to reduce residual risk with Dr. Christie Ballantyne, Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine.  Based on popular demand this episode, originally aired in August 2023, is being republished for our audience. This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Christie Ballantyne.  Dr. Ballantyne is a Professor of Medicine-Cardiology, and Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine. Selected references in the Podcast: Niacin: AIM-HIGH - N Engl J Med 2011; 365:2255-2267 Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280 Pemafibrate: PROMINENT - N Engl J Med 2022; 387:1923-1934 Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098 Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168  

durée : 00:04:07 - Le Musée Serret de Saint-Amarin - Le musée Serret à Saint Amarin , à visiter avant la fermeture hivernale le 17novembre 2024. Das Serret-Museum in Saint Amarin, zu besichtigen vor der Winterschließung am 17. November 2024

durée : 00:02:07 - Le musée numérique Micro-Folies - Et si les musées parisiens emménageaient dans la Vallée de Saint-Amarin ? Le projet Micro-Folie s'inscrit dans un réseau de plusieurs centaines de Micro-Folies, soutenu par le Ministère de la Culture et accompagné par le Ministère de la Cohésion des Territoires.

In this special episode titled “Lipids – Beyond Statins and LDL Cholesterol”, our host, Dr. Neil Skolnik will discuss with two expert guests the details of treatment for LDL-Cholesterol, Triglycerides, and other lipid risk markers.  This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health James Underberg, M.D. , Clinical Assistant Professor of Medicine at NYU School of Medicine and the NYU Center for Prevention of Cardiovascular Disease, Director of the Bellevue Hospital Lipid Clinic, and Past President of the National Lipid Association. Layla A. Abushamat, M.D., MPH, Assistant Professor, Department of Medicine in the Division of Atherosclerosis and Vascular Medicine, Baylor College of Medicine,  Houston, Texas   Selected references referred to the in the Podcast: 1.     Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 2.     Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280 3.     Lipoprotein(a) Blood Levels and Cardiovascular Risk Reduction With Icosapent Ethyl. JACC. 2024 Apr, 83 (16) 1529–1539 4.     Icosapent ethyl following acute coronary syndrome. European Heart Journal 2024; 45:1173–1176 5.     Cardiovascular Disease and Risk Management: ADA Standards of Care in Diabetes—2024. Diabetes Care 2024;47(supp 1): S179–S218

durée : 00:04:05 - Denne Summer im Müsé Serret in Santamari (Saint-Amarin) - Le Musée Serret présente depuis le 19 avril sa nouvelle exposition : « L'évolution de la photographie »

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology this Week: A concise summary of recent studies   Lifetime management of aortic valve stenosis   Spirituality and cardiovascular health  Statistics Made Easy: Statistical Analyses using Chat GPT  Host: Perry Elliott Guests: Carlos Aguiar, Kavitha Chinnaiyan, Francesco Maisano Want to watch that episode? Go to: https://esc365.escardio.org/event/1155   Disclaimer ESC TV Today and ESC 365, the cardiology knowledge hub are supported by Bristol Myers Squibb. The scientific content and opinions expressed in this programme have not been influenced in any way by its sponsor. This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC.   Declarations of interests Stephan Achenbach, Kavitha Chinnaiyan and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Giuseppe Biondi-Zoccai has declared to have potential conflicts of interest to report : Aleph, Amarin, Balmed, Cardionovum, Crannmedical, Endocore Lab, Eukon, Guidotti, Innovheart, Meditrial, Menarini, Microport, Opsens Medical, Terumo, and Translumina. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi, Terumo, Medtronic. Perry Elliott has declared to have potential conflicts of interest to report: consultancies for Pfizer, BMS, Cytokinetics. Francesco Maisano has declared to have potential conflicts of interest to report : Grant Institute, Edwards, Abbott, NVT, Medtronic, Jenavalve and Boston Scientifics. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.      

In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Metabolic Syndrome: A Focus on Triglycerides with Dr. Peter Toth.  Dr. Toth is Director of Preventive Cardiology, CGH Medical Center, and an adjunct professor of medicine at Johns Hopkins Medical School. This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Peter Toth, M.D.,PhD,   Director of Preventive Cardiology, CGH Medical Center, Adjunct Professor of Medicine, Johns Hopkins Medical School.  Selected references  in the Podcast: Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280 Pemafibrate: PROMINENT - N Engl J Med 2022; 387:1923-1934 Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098 Regular use of fish oil supplements and course of cardiovascular diseases: prospective cohort study.BMJMED 2024;3:e000451

ESC TV Today brings you concise analysis from the world's leading experts, so you can stay on top of what's happening in your field quickly. This episode covers: Cardiology This Week: A concise summary of recent studies All you need to know about omega-3 fatty acids Lead induced tricuspid regurgitation MythBusters: Pomegranates are heart-healthy Host: Rick Grobbee Guests: Carlos Aguiar, Martin Andreas, Deepak Bhatt Want to watch that episode? Go to: https://esc365.escardio.org/event/1150 Disclaimer This programme is intended for health care professionals only and is to be used for educational purposes. The European Society of Cardiology (ESC) does not aim to promote medicinal products nor devices. Any views or opinions expressed are the presenters' own and do not reflect the views of the ESC. Declarations of interests Stephan Achenbach, Rick Grobbee and Nicolle Kraenkel have declared to have no potential conflicts of interest to report. Carlos Aguiar has declared to have potential conflicts of interest to report: personal fees for consultancy and/or speaker fees from Abbott, AbbVie, Alnylam, Amgen, AstraZeneca, Bayer, Boehringer-Ingelheim, Daiichi-Sankyo, Ferrer, Gilead, Lilly, Novartis, Pfizer, Sanofi, Servier, Tecnimede. Martin Andreas has declared to have potential conflicts of interest to report: proctor/speaker/consultant (Edwards, Abbott, Medtronic, Boston, Braun, Zoll) and institutional Research Grants (Edwards, Abbott, Medtronic, LSI). Deepak Bhatt has declared to have potential conflicts of interest to report: research funding from Amarin paid to Brigham and Women's Hospital and the Icahn School of Medicine at Mount Sinai for my role as Principal Investigator of REDUCE-IT. Davide Capodanno has declared to have potential conflicts of interest to report: Abbott Vascular, Novo Nordisk, Sanofi. Terumo, Medtronic. Emma Svennberg has declared to have potential conflicts of interest to report: institutional research grants from Abbott, Astra Zeneca, Bayer, Bristol-Myers, Squibb-Pfizer, Boehringer-Ingelheim, Johnson & Johnson, Merck Sharp & Dohme.

Amarin Pharma, Inc. v. Hikma Pharmaceuticals USA Inc.

In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Residual Risk, Triglycerides and how to reduce residual risk with Dr. Charles Vega, Clinical Professor of Family Medicine and Associate Dean in the School of Medicine at the University of California, Irvine. This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Charles Vega, M.D., Clinical Professor of Family Medicine, Director, UC Irvine Program in Medical Education for the Latino Community, and Associate Dean in the School of Medicine at the University of California, Irvine.   Selected references referred to the in the Podcast: Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168 See Episode 1 for further references.

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben a Mardock Scramble című animéről lesz szó. Linkek az animéhez: MAL: https://myanimelist.net/anime/8100/Mardock_Scramble__The_First_Compression Visszajelzéseket szívesen fogadjuk. Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

Featuring leading cardiology experts, this podcast episode navigates atherosclerotic cardiovascular disease (ASCVD), including plaque morphology, residual risk, secondary treatment options, and guidelines from the National Institute for Health and Care Excellence (NICE). They also detail how these different treatment options work, and conclude the episode by sharing relevant patient case studies that reflect the themes discussed.   Lale Tokgözoğlu, Professor of Cardiology, Hacettepe University, Ankara, Turkey; and Pierre Sabouret, Heart Institute, ACTION Study Group-CHU Pitié-Salpêtrière University Hospital, Paris, France, join EMJ to share their expert insights on this pertinent topic.   Following the recording of this podcast the European Society of Cardiology (ESC) 2023 Guidelines have been updated. Please refer to your local guidelines and relevant prescribing information for the most up-to-date information.   Disclaimer: This podcast is sponsored by an educational grant by Amarin. The speakers opinion is entirely their own and did not receive an honorarium for their part.

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben a Xam'd Lost Memories című animéről lesz szó. Linkek az animéhez: MAL: https://myanimelist.net/anime/4177/Bounen_no_Xamdou Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

In this special episode on Residual Risk: A Focus on Triglycerides, our host, Dr. Neil Skolnik will discuss Residual Risk, Triglycerides and how to reduce residual risk with Dr. Christie Ballantyne, Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine. This special episode is supported by an independent educational grant from Amarin. Presented by: Neil Skolnik, M.D., Professor of Family and Community Medicine, Sidney Kimmel Medical College, Thomas Jefferson University; Associate Director, Family Medicine Residency Program, Abington Jefferson Health Dr. Christie Ballantyne.  Dr. Ballantyne is a Professor of Medicine-Cardiology, and Director of the Center for Cardiometabolic Disease Prevention, Baylor College of Medicine. Selected references in the Podcast: Niacin: AIM-HIGH - N Engl J Med 2011; 365:2255-2267 Omega-3 Fatty Acids: STRENGTH trial - JAMA. 2020;324(22):2268-2280 Pemafibrate: PROMINENT - N Engl J Med 2022; 387:1923-1934 Icosapent Ethyl: JELIS - Lancet. 2007;369(9567):1090-1098 Icosapent Ethyl: REDUCE-IT - N Engl J Med 2019; 380:11-22 ADA Standards of Care: Diabetes Care 2023;46(Supplement_1):S158–S190 2023 AHA/ACC/ACCP/ASPC/NLA/PCNA Guideline for the Management of Patients With Chronic Coronary Disease: Circulation. 2023;148. doi: 10.1161/CIR.0000000000001168

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben a Suzume című animéről lesz szó. Linkek az animéhez: MAL: https://myanimelist.net/anime/50594/Suzume_no_Tojimari Visszajelzéseket szívesen fogadjuk. Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben a Carole & Tuesday című animéről lesz szó. Link az animéhez: MAL: https://myanimelist.net/anime/37435/Carole___Tuesday Visszajelzéseket szívesen fogadjuk. Mono: https://music.youtube.com/playlist?list=OLAK5uy_mRVXRS8M4NEzRGm9fySImAoyTjyalGxJE&feature=share Szesztay Dávid: https://music.youtube.com/channel/UC174Bru-Ed1D13L5UJC2hzg?feature=share Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

Ebben a részben a Vivy: Fluorite Eye's Song című animéről lesz szó. Linkek az animéhez: MAL: https://myanimelist.net/anime/46095/Vivy__Fluorite_Eyes_Song Visszajelzéseket szívesen fogadjuk. Megemlített dolgok: Atis 4 napos munkaidő videó: https://youtu.be/1S7mbmLXFc4 21:9 vs 16:9 vs 4:3 imax: https://youtu.be/9-pPB75hH2Q "Her" című film: https://www.imdb.com/title/tt1798709/ Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

Szia én Leírás senpai vagyok, kérlek figyelj rám! Weboldal: https://gondolatokafejben.hu/animecricast Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

Some expect the next few years will be an overall down period for pharma growth. So, Fierce's Kevin Dunleavy invited Harietta Eleftherochorinou, Ph.D., of IQVIA to "The Top Line" to discuss why pharma needs to employ artificial intelligence and machine learning tools to stay ahead of the curve. To learn more about the topics in this episode:  2023 forecast: An 'inflection point' for biopharma, fueled by a flood of AI and machine learning products Covis finally pulls preterm birth drug Makena after 12-year accelerated approval odyssey FDA sounds out de novo clearance for neuromodulation device to treat tinnitus FDA widens Lilly's Verzenio breast cancer reach, removes test and menopausal status demands Sarissa's overhaul of Amarin's board is complete with resignation of 7 holdover members AbbVie CEO Gonzalez scored $26M in 2022 pay as cash cow Humira neared patent cliff FDA delays BioMarin's gene therapy approval decision by 3 months The Top Line is produced by senior multimedia producer Teresa Carey and managing editor Querida Anderson with editor-in-chief Ayla Ellison and senior editors Annalee Armstrong, Ben Adams, Conor Hale and Eric Sagonowsky. The sound engineer is Caleb Hodgson. The stories are by all our “Fierce” journalists. Like and subscribe wherever you listen to your podcasts.See omnystudio.com/listener for privacy information.

Linkek az animéhez: BNA: https://myanimelist.net/anime/40060/BNA Girls' LastTour: https://myanimelist.net/anime/35838/Shoujo_Shuumatsu_Ryokou ID: Invaded: https://myanimelist.net/anime/40046/Id_Invaded Visszajelzéseket szívesen fogadjuk. Linkek: MRE evős csatorna: https://www.youtube.com/@LetsGetThisOutOntoATrayNice Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://podcasters.spotify.com/pod/show/animecricast/message

Szia én Leírás senpai vagyok, kérlek figyelj rám! Linkek az animéhez: Yesterday wo Utatte: https://myanimelist.net/anime/39710/Yesterday_wo_Utatte Araburu Kisetsu no Otome-domo yo.: https://myanimelist.net/anime/38753/Araburu_Kisetsu_no_Otome-domo_yo Inuyashiki:https://myanimelist.net/anime/34542/Inuyashiki Megemlített művek: Tsuki ga kirei: https://myanimelist.net/anime/34822/Tsuki_ga_Kirei In Focus: Gáisz: https://infocusuniverse.eu/konyv/ Visszajelzéseket szívesen fogadjuk. Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) Tartalom: 00:00:00 - 00:45:52 Yesterday wo utatte 00:45:52 -01:49:05 Araburu kisetsu 01:49:05 - 02:50:00 Inuyashiki 02:50:00 - Vége --- Send in a voice message: https://anchor.fm/animecricast/message

In this podcast episode, I provide updates to our waterfowl development project if Fulton County, Illinois! We made a few mistakes which we had to correct and learned a bit about how the birds are starting to use our wetlands! We hope you enjoy it. PODCAST TRANSCRIPTION(these are fairly accurate but not perfect…please forgive any errors or inconsistencies) Hey guys, welcome back to the Land Co podcast. This episode is I don’t even know the episode anymore, but it is the Waterfowl Development Series. I’ll put the episode on the notes and the title is probably like episode seven-ish, but I wanted to chat with you guys on the development that we have that Pudik and I have on 135 acres in Canton. Again, we bought that. I think we’re going on a few years now with the goal of making it just like an awesome waterfowl farm. So we’re developing it strictly for waterfowl and. The first several episodes went over what we built the plans and we are at the stage where like we’re we have a few more things to build. But most of the big Earthmoving is done. So now we’re on to like details and getting water to wetlands, getting power places, getting blinds and pits out there. But now where we are at the end of the development, I believe the last episode, we were just getting ready to pump everything full and everything was fine. The only issue we had was if you remember when we we so we pump from our lower wetland and again, I’ll throw pictures on the if you’re listening on like just in your truck like an on Apple podcast hop on the website we we also post these to the website to the, to the blog and on those pages I’ll throw some pictures beneath it if you want to go kind of check out what I’m talking about. But the middle of the 135 is our only like, well, it’s our biggest low ground wetland, like bottom ground, like wet area and it’s I think it’s eight acres, but we pump from there up to a new one that we built that we call a center field wetland, which is historically been like our best dry field. So we’re they seem to like that area. So we’re, we were really excited about that center field wetland. We thought it would do well. Last year we had a. We didn’t have a way to pump water up there. So we were relying strictly on rainwater and it filled it like last year was a good year for filling wetlands with water. And it didn’t even that it didn’t fill it all up. So like it probably folded up halfway. So we never got a sense of how good the wetland was going to be or how much they’d use it. So we knew we had to pump water from the bottom, which we call clam wetland, up about 1000 feet and. We used the corrugated tile and it was like, I don’t think we wouldn’t have done that for a client. I was just sort of curious if that would work. Like you always hear, you know, in our industry, there’s always like all these like old, old legends and like, you know, of what works and what doesn’t. But a lot of them I like. It’s not that I don’t believe them. I’ve just never seen anyone try it like one of them. So like this one, it’s like, Oh, you can’t use corrugated pipe to pump uphill because it’s too much friction and it won’t work. And whatever. We tried it anyways. It was cheaper. You know, we could use that six-inch corrugated like just tile and it was a lot cheaper. So we tried it and again, I had heard that it wouldn’t work, but I’ve never like, I don’t know anyone personally that’s tried it. It’s like, Oh yeah, I tried, but that didn’t work. Everyone’s always like, No, it just doesn’t work. I just know that. All right. Well, we tried it because it was cheaper and like, it didn’t work. So we can officially be like those people that, you know, don’t put corrugated tile into pump uphill because of that pressure. It worked like we got water lay up. But like, eventually the pressure, like not, not like uphill or where it’s coming, like filling the wetland is like the junction. It was just too much pressure. Like it would either blow apart the, like the attachment or like if, you know, because he tried several different things or it was even blowing through the corrugated tile like just past where it attached like the pressure, it was just too much so it didn’t work. Whatever we were, the guinea pigs. We were out a few bucks, but now we know if it worked, we can just save some of our client’s money down the road. So I’m not entirely upset that we tried it, but it didn’t work, so we had to scramble kind of last minute and just do it the right way. And so we had to put in 800 or 1000 feet of PVC tile, kind of like sewage, kind of like drainage tile uphill that 800 to 1000 feet. And once we did, that worked flawlessly. And that’s what we should have done the first time. But it was it’s probably twice as much, but so had to scramble to do that. But that is done and that pumped fine. So we did get to see the wetland has seeped a little bit and we didn’t fill it up probably as much as we should have day one. So it’s not entirely full, but we’re probably six inches to a foot from full. So we got a much better idea of like how that one’s going to work. Gave us kind of an idea of where we’re going to put the blinds next year so we could, you know, we had a good idea, but now we can at least visualize it. And it allowed us to kind of see if the Ducks would use it and we didn’t. Again, we’re purposely, purposefully letting some of the stuff rest. You know, clams has always been there. We fixed it up. But these other wetlands, we’re letting rest for a couple of years. Mike Hitchcock told me that, like he said, if you can let a wetland rest for a few years and we build it to let those birds find it, it’ll help a ton in the long run. And I believe him. I’ve seen his place again. That’s one of the coolest waterfowl farms that I’ve seen. So we, we did that. You know, we have other spots to hunt, so it wasn’t a big deal, but they found that upper wetland, once it was full, they found it in a hurry. So again, it’s only been full for like a week-ish, maybe a little more than that, but as soon as it was full they were on it. So we’re excited to see how it’ll do next year when it’s full from day one. So that went well. Our bottom wetland, not our bottom when we built a little small one acre wetland, but I’m sure we’ve gone over. But that one is below what we call hayfield, and we knew that it wouldn’t fill up every year. It’s just kind of a bonus when we have there was already like a levee there in place. It was a cheap wetland to build last year. It filled up immediately and would have been a cool spot to hunt because it’s right next to this kind of big water. So it’s not something you’re going to hunt, you know, all the time. But when birds are there, it’s a spot you can sneak in and have a good hunt. This year, it just didn’t fill up like there was. There was not enough rain, not nearly enough rain, like there’s not even water in it. So that’s that’s just the nature of the beast on that wetland. Some years it’s going to fill up. Some years is not all the stuff we did on clam taking all that frag mighty out digging all around that so we can plant more. Worked out great. I mean I think when we bought it like and this has been happening slowly over the course of like you know I don’t know how long it’s been there 15 years. It’s just like the little drainage ditches every year, like the mighty and weeds expand out a little bit. So it was in rough shape. We probably doubled what we could plant there, and they’re using that. We did also get in a pit there. We got a Bradley Blind. We talked about that last episode, but we finally got that delivered and installed. That’s going to that’s on the north side of Clam Lake. And again, we won’t hunt that this year. We didn’t have time to you know, we just put it in probably two weeks ago. So. And then you backfill around. There’s a bunch of mud. There’s too much to run in at this point and brush and no big deal. We’ve got other spots to hunt, but it is in for next year. So all we have to do is kind of brush it in for next year. But it’s a cool spot, a cool little shooting hole right in front. And I think that one will do really well, too. So that’s kind of what we’ve we’ve done this year and where we’re at now. So again, the major, the major dirt-moving stuff is all done. We probably will add a few more tillable acres next year. That’s kind of an ongoing thing to try to farm more and more every year and work on some of those spots. But in terms of like waterfowl, you know, the next two or three years, again, it was like kind of a five-year plan. We’re doing some of the stuff in stages just to come up with like a pile of money upfront and one big chunk. Now we’re probably looking at getting the power. We talked about that we’ve met with Amarin and we know what that’s going to run us. But, you know, that might be an issue next year that we’ll tackle. We’ll try to get power down to clam so we can put in an electric pump, and probably run power up to the wetlands so we could run our ice eaters there. That will most likely be what we tackle next year. And then we’re also looking at these don’t we don’t have any blinds, these new wetlands and kind of new spots. The farm is not set up with great blind yet, there are a few pits out there that were there from when we bought it that is good for like field hunting. But in terms of, you know, wetland food hunting, that’s something we’ll have to address next year. So we’ll probably grab another Bradley blind and probably build a few like, you know, just wood frame blinds. So we will tackle that next year as well. And then, you know, then we’re kind of fine-tuning it. So it’s getting close and we’re excited to see how it’ll do next year. But just want to bring you guys up to speed on that project. That’s where we’re at and we’ll keep on it until it’s done. So next year, keeping the loop on what we build, where we put the pitch, and all that stuff. And then hopefully late into next season, we’ll give you a little heads up on how they did, because we’ll start hunting it not not as much as we will the year after, but we’ll probably start dropping in and hunting a few of those spots next year. So that’ll do it for this episode. And we’ll as soon as we, you know, do some more stuff with that project, we’ll come back and do another episode. But that’s where we’re at with that project and I appreciate you guys listening.

Ebben a részben a Mushishi című animéről lesz szó. Link az animéhez: MAL: https://myanimelist.net/anime/457/Mushishi Visszajelzéseket szívesen fogadjuk. Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) --- Send in a voice message: https://anchor.fm/animecricast/message

Aujourd'hui nous allons parler de cohabitation entre VTT et randonneur, est-elle possible ? Dans la Vallée de Saint-Amarin, se trouve l'exemple d'une initiative et une entente réussie entre le club vosgien et les clubS de VTT. Pour en parler nous recevons Joseph Peter, Président du club vosgien départemental du Haut-Rhin et Président de la commission environnement de la fédération du club vosgien. 

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben az összes animéről lesz szó. Linkek az animéhez: AA: https://www.google.hu MAL: https://www.google.hu Visszajelzéseket szívesen fogadjuk. Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) Természetesen a Spoilerezés jogát fent tartjuk! --- Send in a voice message: https://anchor.fm/animecricast/message

Enduring CME will expire on 9/7/2024 Disclosures: Grant/research support: Amarin, Amgen, Boehringer Ingelheim Objectives: 1. To review the cellular and molecular basis of vascular calcification 2. To review population studies of coronary calcification 3. To understand the clinical utility of coronary artery calcification (CAC) testing Accreditation and Designation: The Northeast Georgia Medical Center & Health System, Inc. is accredited by the Medical Association of Georgia to provide continuing medical education for physicians. The Northeast Georgia Medical Center & Health System, Inc. designates this live activity for a maximum of 1 AMA PRA Category 1 Credit(s) TM. Physicians should only claim credit commensurate with the extent of their participation in the activity.

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben ezekről az animéről lesz szó: Linkek az animéhez: 1. Kimi no na wa: https://myanimelist.net/anime/32281/Kimi_no_Na_wa?q=Kimi%20no%20na%20wa&cat=anime - Tenki no ko 2. Josee to Tora to Sakana-tachi: https://myanimelist.net/anime/40787/Josee_to_Tora_to_Sakana-tachi?q=josee&cat=anime - Koe no Katachi 3. Suzumiya Haruhi no Shoushitsu: https://myanimelist.net/anime/7311/Suzumiya_Haruhi_no_Shoushitsu?q=suzumiya%20haru&cat=anime - Kara no Kyokai 4. Kimi no Suizou wo Tabetai (Palacsinta): https://myanimelist.net/anime/36098/Kimi_no_Suizou_wo_Tabetai?q=i%20want%20to%20eat%20yo&cat=anime 5. 5cm/s: https://myanimelist.net/anime/1689/Byousoku_5_Centimeter? 6. Maquia: https://myanimelist.net/anime/35851/Sayonara_no_Asa_ni_Yakusoku_no_Hana_wo_Kazarou?q=maquia&cat=anime q=five%20centimeter&cat=anime 7. Garden of words: https://myanimelist.net/anime/16782/Kotonoha_no_Niwa?q=garden%20of%20wo&cat=anime 8. Given (filmje): https://myanimelist.net/anime/40421/Given_Movie?q=given&cat=anime - Doukyuusei (Movie) - Yuri!!! On ice - Dakaretai Otoko 1-i ni Odosarete Imasu. - K (project k) - Sakamichi no Apollon - Bloom in to You 9. Her Blue Sky: https://myanimelist.net/anime/39569/Sora_no_Aosa_wo_Shiru_Hito_yo?q=her%20blue%20sky&cat=anime Fogalmam sincs mikor említettük meg (Starlis), de nem a H2O volt az, hanem a: One: Kagayaku Kisetsu e (Saját felelősségre, mert az egyik változata hentai!) Megemlített animék a végén: Hotarubi no Mori e: https://myanimelist.net/anime/10408/Hotarubi_no_Mori_e?q=hota&cat=anime Napping Princess: https://myanimelist.net/anime/33204/Hirune_Hime__Shiranai_Watashi_no_Monogatari?q=napping%20pr&cat=anime SAO film Ordinal Scale: https://myanimelist.net/anime/31765/Sword_Art_Online_Movie__Ordinal_Scale?q=ordinal&cat=anime Hotaru no Haka: https://myanimelist.net/anime/578/Hotaru_no_Haka?q=Hotaru%20no%20haka&cat=anime In This Corner of the World: https://myanimelist.net/anime/15227/Kono_Sekai_no_Katasumi_ni?q=Kono%20sekai%20no%20katasumi%20ni&cat=anime A LN amit Starlis mondott az 1000 évig élő lányról és a macaronról: https://myanimelist.net/manga/78241/Macaron_Daisuki_na_Onnanoko_ga_Dounika-Kounika_Sennen_Ikitsuzukeru_Ohanashi A hangoskönyv, amiben Rin, Chun és Starlis szerepel: https://youtu.be/BZajzQ27Thw Animegyetem (Mondo kereskasztal) Atisos kerekasztal: (ha felkerül Yt-ra, akkor iderakom a linket) Visszajelzéseket szívesen fogadjuk. Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) Időbélyegek 00:00:00 - Bevezetés 00:02:34 - Kimi no na wa 00:19:12 - Josee to Tora to Sakana-tachi 00:34:56 - Suzumiya Haruhi no Shoushitsu 00:56:34 - Kimi no Suizou wo Tabetai 01:18:01 - 5cm/s 01:44:05 - Maquia 02:00:36 - Garden of Words 02:13:35 - Given film 02:53:23 - Her Blue Sky 03:14:19 - A többi megemlítésre méltó vagy nem méltó anime 03:28:03 - Levezetés --- Send in a voice message: https://anchor.fm/animecricast/message

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben a Re:Zero című animéről lesz szó. Link az animéhez MAL: https://myanimelist.net/anime/31240/Re_Zero_kara_Hajimeru_Isekai_Seikatsu?q=re%3Azero&cat=anime Visszajelzéseket szívesen fogadjuk. Linkek: Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) Természetesen a Spoilerezés jogát fent tartjuk! --- Send in a voice message: https://anchor.fm/animecricast/message

Szia én Leírás senpai vagyok, kérlek figyelj rám! Ebben a részben az Odd Taxi című animéről lesz szó. Link az animéhez: MAL: https://myanimelist.net/anime/46102/Odd_Taxi?q=odd%20taxi&cat=anime Visszajelzéseket szívesen fogadjuk. Linkek: Podcast elérhetőség: https://anchor.fm/animecricast https://open.spotify.com/show/4BaazPQvrFjBXUDMxojmhN Atis: https://www.youtube.com/c/Animegyetemvlog Kitti: https://www.youtube.com/channel/UCGBjFqolDenjX1pRMysI_1w Twitter, ha szeretnél kérdezni tőlünk valamit: Fő Twitter: https://twitter.com/AnimeCricast https://twitter.com/Starlis_km https://twitter.com/Amarin_dk https://twitter.com/ChunRaps Lenne anime ajánlásod? Itt megteheted: https://forms.gle/817AfJtF6kLqTfWp9 Felvezető zene: Aimee Blackschleger - No differences (a0v) Természetesen a Spoilerezés jogát fent tartjuk! --- Send in a voice message: https://anchor.fm/animecricast/message

Welcome back to True to Your Heart, brought to you by Amarin. Joining our host Ron Jaworski on the show today is Ron Ryder, Doctor of Osteopathic Medicine and Medical Director of Hamilton Cardiology Associates ICANL Accredited Nuclear Cardiology Lab and chairman of the Quality Committee. Dr. Ryder is with us to discuss why cardiovascular disease is such an important issue, why decreasing risk is a question of lifestyle, and even give us his own recommendations for heart health resolutions in 2022. Today's show is all about simple and effective ways you can direct energy into keeping your heart healthy. Later, Ron will be joined by Michael Chernow, a man who wears many hats. Michael is the CEO and Founder of Creatures of Habit, Founder of Seamore's, the Co-Founder of the Meatball Shop, as well as an Entrepreneur and Branding Expert too. He's here today to tell us a little bit more about some of the lifestyle choices we can make to keep our heart healthy all year long.  Follow UsTwitter @JawsCEOQBFacebook @jawsceoqbInstagram @jawsceoqbPresented by Amarinhttps://truetoyourheart.com

Welcome back to True to Your Heart, brought to you by Amarin. Joining Ron Jaworski on the show today is Specalist of Non-Invasive Cardiology at The Harford Healthcare Medical Group, Dr. Brett Nowlan, and Executive Director at The Mended Hearts Organization, Dr. Andrea Baer. February is ‘American Heart Month' and highlights how even after such a harrowing struggle against COVID-19, heart disease continues to be the leading cause of death in the United States. Our guests today discuss tangible lifestyle changes that are easy to make and have long lasting benefits for your heart. Plus, they'll give you some of the top indicators for tracking your heart health and bust some common myths about heart health and who should be paying attention to it. Follow UsTwitter @JawsCEOQBFacebook @jawsceoqbInstagram @jawsceoqbPresented by Amarinhttps://truetoyourheart.com

On this episode of Aftershocks Tremors, we sit down with drummer Zed Amarin and guitarist/vocalist Michael Nolasco from Jordanian thrash metal veterans ESODIC. The guys chat about the bands new single 'Undoing', the bands origins in the Middle East and the legal ramifications that came with being in a metal band and scene in Jordan, Amarin's relocation to Los Angeles and teaming up with Nolasco ,what the future of Esodic music will sound like and much more. --- Send in a voice message: https://anchor.fm/cmspn/message

On this episode of Aftershocks Tremors, we sit down with drummer Zed Amarin and guitarist/vocalist Michael Nolasco from Jordanian thrash metal veterans ESODIC. The guys chat about the bands new single 'Undoing', the bands origins in the Middle East and the legal ramifications that came with being in a metal band and scene in Jordan, Amarin's relocation to Los Angeles and teaming up with Nolasco ,what the future of Esodic music will sound like and much more. 

Welcome back to True to Your Heart, brought to you by Amarin. Joining Ron Jaworski on the show today are doctors Steve Edelman and Schafer Boeder. They're here to discuss how diabetes can impact your heart health and give expert advice on how those with diabetes can address both. Dr. Edelman is the founder and director of the ‘Taking Control of Your Diabetes' organization, a Professor of Medicine in the Division of Endocrinology - Diabetes & Metabolism at the University of California, San Diego, and the Director of the Diabetes Care Clinic at the VA Medical Center. Dr. Boeder is a Co-Director, Endocrinologist, and Assistant Professor of Medicine at the UCSD School of Medicine and is also an educator for organizations like ‘Taking Control of your Diabetes.' Today they both help discuss little-known side effects of diabetes like cardiovascular disease, lifestyle tips to drastically reduce one's risk for heart disease, diabetes mythbusters, and more!Follow UsTwitter @JawsCEOQBFacebook @jawsceoqbInstagram @jawsceoqbPresented by Amarinhttps://truetoyourheart.com

On this week's episode of True To Your Heart presented by Amarin, we are discussing cardiovascular health among minority communities. Ron Jaworski gets a chance to sit down with Dr. Kenton Forte, an Assistant Clinical Professor at SUNY in Buffalo, who has been practicing internal medicine at the Heart Beat Center of Western New York for over 22 years. Together they talk about how different social determinants such as education, housing, stress and more can impact your overall health as a person. Did you know 80% of a human's health is determined by nonclinical factors? The social determinants of health are very important in terms of your everyday environment from school to nutrition to where you live. It's about prevention rather than intervention! Learn firsthand from Dr. Forte some of the different preventative measures you can take to safeguard your health and your future through understanding the contributing factors behind cardiovascular disease. He also discusses exercise plan recommendations and how they correlate with the proper diet! Also, hear about the work he is doing with the Greater Buffalo United Accountable Care Organization to bring awareness about heart health to minority communities. Later on the show, Ron will be speaking with the CEO of Diabetes Sisters, Anna Norton! Diabetes Sisters is a non-profit organization that offers a range of education and support services to help women of all ages with all types of diabetes live healthier, fuller lives. They create opportunities for peer support and education with a goal for women to form a special bond and freely share information, helpful tips, and stories of hope. Hear Ron and Anna talk about how diabetes affects underserved communities and how it can relate to other cardiovascular diseases! Together the two break down some of the environmental and social factors that are affecting the cardiovascular health of different minority communities.To learn more: https://truetoyourheart.com00:00:00 - Intro00:01:31- Interview with Dr. Forte00:17:52 - Interview Anna NortonPresented by Amarin

This week, former NFL Running back and ESPN Analyst Merril Hoge joined Ron to discuss how surviving open-heart surgery and Non-Hodgkin's Lymphoma had an impact on his health journey. Ron also sat down with Dr. Peter Toth, the Director of Preventive Cardiology at the CGH medical center in Sterling, Illinois. Their conversation focused around the importance of not just preventive care, but early preventive care when it comes to men and their heart health. They also discuss some of the early signs of heart disease, how to manage them and how to break the stigma of reaching out for care. To learn more: https://truetoyourheart.com00:00:00 - Intro00:01:49 - Interview with Dr. Peter Toth00:16:01 - Interview with Merril HogePresented by Amarin 

This week we are focusing on women and their heart health. Ron Jaworski sit's down with Dr. Payal Kohli, a noninvasive cardiologist and founding partner of Cherry Creek Heart in Denver. Dr. Kohli explains to us how heart disease affects women differently, and how cardiovascular health is just as important for women as it is for men. Later, Ron is joined by the CEO of Healthy Women, Beth Battaglino, to further discuss how important preventive care is for your health. Is it fact or fiction? Beth then rolls through a round of myth-busters to help clear up any questions we might have when it comes to heart disease. To learn more: https://truetoyourheart.com00:00:00 - Intro00:01:54 - Interview with Dr. Kohli 00:16:00 - Interview Beth BattaglinoPresented by Amarin

This week, host Ron Jaworski is joined by Dr. Dean G. Karalis and TV Health Expert Joy Bauer to discuss the importance of making your heart health a priority again. As an expert in lipidology and cardiology, Dr. Karalis has seen firsthand the effects the pandemic has had on cardiovascular health in the U.S. He shares with Ron the advice he gives to patients so that they can re-take charge of their health journey. Later, Joy gives Ron her tips on how you can steer yourselves toward a healthy diet that makes sense for your lifestyle.To learn more: https://truetoyourheart.com00:00:00 - Intro00:01:42 - Interview with Dr. Karalis 00:16:44 - Interview Joy BauerPresented by Amarin

On episode 2 of Dumb and Drummer we have Zed Amarin who is the head artist rep for Axis Percussion in Carson CA. We talk about business during a pandemic And new stuff coming from Axis!   website:www.axispercussion.com Instagram: @axispercussionofficial @zedamarin